finanzen.net
12.02.2019 00:08
Bewerten
(0)

The myocardial infarction (MI) therapeutics market will register a CAGR of almost 3% by 2023

DRUCKEN

LONDON, Feb. 11, 2019 /PRNewswire/ -- About this market
MI along with other cardiovascular problems, is the leading cause of premature deaths in the world. The rising incidence of coronary artery disease, obesity, diabetes, and hypertension, along with a sedentary lifestyle, smoking, and reduced physical activities, is expected to increase the risk factors for cardiovascular diseases including MI. Apart from these factors, the rapid rise in the geriatric population is increasing the incidence of MI. Hence, the incidence of MI is expected to increase with the rapidly expanding geriatric population. The rising incidence of MI will propel the growth of the market during the forecast period. Technavio's analysts have predicted that the myocardial infarction (MI) therapeutics market will register a CAGR of almost 3% by 2023.

Download the full report: https://www.reportbuyer.com/product/5734241

Market Overview
Increased adoption of novel antithrombotics
Novel antithrombotics such as NOACs and antiplatelet drugs (BRILINTA and Effient) possess the potential to expand the scope of the treatment for MI. These drugs offer significant advantages such as target specificity. The market also contains specific antidotes for these drugs. which can help prevent life-threatening or uncontrolled bleeding.
Extensive use of generics
A generic drug is a medication that is the same as the existing approved branded drug in terms of dosage form, safety, strength, route of administration, quality, and performance characteristics. Generic drugs are allowed for sale after the expiry of the patent of the original branded drug. Thus, generic drugs have comparatively lower prices than the branded drugs.
For the detailed list of factors that will drive and challenge the growth of the myocardial infarction (MI) therapeutics market during the 2019-2023, view our report.

Competitive Landscape
The market appears to be moderately concentrated and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Download the full report: https://www.reportbuyer.com/product/5734241

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/the-myocardial-infarction-mi-therapeutics-market-will-register-a-cagr-of-almost-3-by-2023-300793085.html

SOURCE ReportBuyer

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX startet höher -- Asiens Börsen fester -- Deutsche Telekom toppt Erwartungen und erhöht Dividende -- Trump erwägt weiter Zölle auf EU-Autoimporte -- Fielmann, Henkel im Fokus

Pfeiffer Vacuum steigert Umsatz stärker als erwartet. Naturkatastrophen zerfleddern erneut Gewinn der Swiss Re. Samsung bringt aufklappbares Smartphone für 2000 Euro auf den Markt. FUCHS PETROLUB verdient dank niedrigerer Steuern mehr. Abschreibung auf US-Tochter drückt auf AXA-Gewinn.

Die 5 beliebtesten Top-Rankings

Das sind die reichsten Länder Welt 2018
USA nicht mal in den Top 10
Abschlüsse der DAX-Chefs
Diese Studiengänge haben die DAX-Chefs absolviert
Erster Job
Wo Absolventen am meisten Geld verdienen
Die weltweit größten Smartphone-Hersteller
Der Worldwide Quarterly Mobile Phone Tracker
StepStone Gehaltsreport 2019
So viel verdienen die Deutschen in diesen Branchen
mehr Top Rankings

Umfrage

Sind Sie in Cannabis-Aktien investiert?

finanzen.net Brokerage

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Daimler AG710000
Deutsche Bank AG514000
Deutsche Telekom AG555750
CommerzbankCBK100
Amazon906866
Fresenius SE & Co. KGaA (St.)578560
Apple Inc.865985
Aurora Cannabis IncA12GS7
Allianz840400
Volkswagen (VW) AG Vz.766403
BASFBASF11
SteinhoffA14XB9
TUI AGTUAG00
NEL ASAA0B733